Cafepharma Today

May 30 2025 - #ASCO25 tracker: Meeting kicks off in Chicago with high expectations in breast, lung cancer
#ASCO25 tracker: Meeting kicks off in Chicago with high expectations in breast, lung cancer
Roche links BTK inhibitor to low relapse rate across 96-week multiple sclerosis trial
Mixed COPD results for Regeneron, Sanofi drug cloud approval chances
Illumina introduces a new AI algorithm PromoterAI
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

The Risk For Bristol
Forbes
Monday, June 7, 2010 - 7:48am
tags:
Bristol-Myers Squibb, melanoma, ASCO, ipilimumab
Randomized Phase III Study Comparing REVLIMID(R) Plus Melphalan and Prednisone (MPR) Compared to Autologous Stem Cell Transplant Presented at ASCO
MarketWatch
Sunday, June 6, 2010 - 12:34pm
tags:
Multiple Myeloma, Revlimid, melphalan, autologous stem cell transplant, Celgene
Phase III Study Results Showed Eisai’s Eribulin Mesylate Significantly Improved Overall Survival in Patients with Locally Recurrent or Metastatic Breast Cancer
BusinessWire
Sunday, June 6, 2010 - 12:31pm
tags:
Eisai, Eribulin Mesylate, breast cancer
Researchers Report Treatment Headway Against Lung Cancer
BusinessWeek
Sunday, June 6, 2010 - 11:52am
tags:
crizotinib, non-small cell lung cancer, Pfizer
Targeted Therapy Shows Promise Against Deadly Brain Cancer
BusinessWeek
Sunday, June 6, 2010 - 11:50am
tags:
medulloblastoma, brain cancer, GDC-0449, Pfizer
Pharmacovigilance - legislative update (In Europe)
European Public Health Alliance
Sunday, June 6, 2010 - 11:37am
tags:
Europe
Awash in cash and possibilities, Isis Pharmaceuticals forges ahead
North Country Times, CA
Sunday, June 6, 2010 - 11:33am
tags:
Isis Pharmaceuticals, mipomersen, Genzyme, cholesterol
Delcath Highlights Phase III Trial Results Presented at ASCO
Trading Markets
Sunday, June 6, 2010 - 11:17am
tags:
melphalan, ocular melanoma, melanoma
Erbitux May Not Help Colon-Cancer Survival for Some, Study Says .
WSJ
Sunday, June 6, 2010 - 11:10am
tags:
Eli Lilly, ImClone, Erbitux, colon cancer
What Lies Ahead for Javelin Pharmaceuticals?
Seeking Alpha
Sunday, June 6, 2010 - 11:07am
tags:
Javelin, M&A
FDA Committee Votes to Reject AstraZeneca RSV Drug: Biotech's Latest Mishaps
Seeking Alpha
Sunday, June 6, 2010 - 11:03am
tags:
RSV, AstraZeneca, MedImmune, motavizumab, Axanum
Javelin / Hospira Relationship Sours as Writs Fly
Seeking Alpha
Sunday, June 6, 2010 - 11:00am
tags:
Javelin, Hospira, investors
Amgen's Hopes for Prolia Go Beyond Osteoporosis Therapy
Seeking Alpha
Sunday, June 6, 2010 - 10:57am
tags:
Amgen, Prolia, osteoporosis, Bone metastases
New AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer
Yahoo/PR NewsWire
Sunday, June 6, 2010 - 10:54am
tags:
Amgen, AMG 386, paclitaxel, ovarian cancer
OXiGENE Reports Encouraging Safety and Efficacy Data from Ongoing Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer at the 2010 ASCO Annual Meeting
Yahoo/Globe NewsWire
Sunday, June 6, 2010 - 10:53am
tags:
Oxigene, non-small cell lung cancer, Zybrestat
Pooled Results of Early Endpoints from Phase 3 Trials of Genasense® in Advanced Melanoma Presented at ASCO
Yahoo/BusinessWire
Sunday, June 6, 2010 - 10:51am
tags:
Genta, melanoma, Genasense
Illumina Takes the Lead in Human Genome Project
Seeking Alpha
Sunday, June 6, 2010 - 10:48am
tags:
Illumina, genome sequencing
Results of Phase 3 ABRAXANE® Combination Trial In First-Line Non-Small Cell Lung Cancer Show 31 Percent Improvement In Response Rate Compared With Taxol Combination
BusinessWire
Saturday, June 5, 2010 - 12:34pm
tags:
Abraxane, Taxol, carboplatin, companies, non-small cell lung cancer
Melanoma drug a seismic shift in cancer
MSNBC
Saturday, June 5, 2010 - 12:31pm
tags:
melanoma, ipilimumab
Phase 3 Study Showed MACUGEN® Improved Vision Over Standard of Care in Patients with Diabetic Macular Edema
PR NewsWire
Saturday, June 5, 2010 - 12:29pm
tags:
diabetic macular edema, Macugen, Pfizer

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline
Lose Your Crystalline Form and Go Amorphous
In the Pipeline
Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.